Portfolio Category: Cancer

Cancer is a disease of the genome. Genomic somatic mutations and alterations can change the function of genes, either promoting the expression of cancer causing genes or the loss of cancer suppressor genes. These genomic mutations/alterations drive cancer development, progression and ultimately drug resistance. The major research interest of the translational cancer genomic research lab…

Biotherapeutics (biologics or biotech drugs) are at the forefront of modern cancer chemotherapy. Examples include the monoclonal antibodies Herceptin ®, Erbitux ® and Perjeta ® , the antibody drug conjugate Kadcyla ®, the immune checkpoint inhibitors Opdivo ® and Yervoy ® and the angiogenesis inhibitor Avastin ®. These therapies are at the forefront of the…

The Targeted Therapies for Cancer research is focused on two key areas: i) preclinical evaluation of novel targeted therapies in specific cancer subtypes and ii) investigation of mechanisms of response/resistance to targeted therapies in cell line models. Our current research includes projects on HER2 positive breast cancer, triple negative breast cancer and melanoma. We are…

Uveal Melanoma Research Using Proteomic Methods Uveal melanoma is the most common intraocular malignancy in adults. The survival rate of uveal melanoma patients who develop metastatic disease is very poor, with few therapeutic options available to treat advanced disease. We are using proteomic methods, e.g. quantitative label-free LC-MS, to understand progression of metastasis in uveal…

Pancreatic Cancer Research Programme The pancreatic research programme focuses on understanding the molecular mechanisms of drug resistance, invasion and metastasis in pancreatic cancer, in collaboration with Dr. Ray McDermont, Dr. Niall Swan and the surgical team at St. Vincent's Hospital and Dr. Gerard McVey and Prof. Michael Moriarty at St.Luke's Hospital. Key areas of research…

Novel ADC targets & Monoclonal Antibodies for Biopharmaceuticals Therapeutic antibodies are the largest class of biopharmaceuticals for human disease. Development of more effective therapeutic strategies for cancers of high unmet need requires the continued discovery of disease specific cell surface protein targets for such therapeutic antibody targeting. Antibody Drug Conjugates (ADCs) are an emerging class…

Multiple Myeloma - Personalized Medicine Personalized Medicine in practice; Discovery of Potential Proteomic Biomarkers For Predicting the Drug Response in Patients with Multiple Myeloma. Personalized medicine is about making the treatment as individualized as the disease. It involves identifying genetic, proteomic, and other related information that allows accurate predictions to be made about a person's…

Lung cancer is the second most common cancer in men and women (excluding skin cancer) in the US and third most common in Ireland.  However, lung cancer is the leading cause of cancer deaths accounting for about 27%.  The mortality rates are a reflection of the advanced stage of the disease in which more than…